This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
  • Pre-Assessment
  • Activity
  • Post-Test
  • Evaluation
  • Claim Credit
Questions about our CME?
Questions about our CME?
Beneath the Surface: Psoriatic Arthritis in Dermatology Practice—Simulations

Beneath the Surface: Psoriatic Arthritis in Dermatology Practice—Simulations

Format

Patient Case Simulations

Time to Complete

45 minutes

Released

June 7, 2018

Expires

June 7, 2019
Add to Queue


Maximum Credits

0.75 / AMA PRA Category 1 CreditTM

Accredited Provider



This activity is provided by Forefront Collaborative.

Commercial Supporter

This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

Program Description

Two case simulations are the core of this enduring activity. Each simulation will allow participants to explore a clinical vignette of a patient with psoriasis and psoriatic arthritis (PsA) and make a treatment decision, choosing from the available options. The activity also includes three concise presentations that were recorded during a live event that took place in conjunction with the 2018 Maui Derm for Dermatologists meeting. The first presentation reviews the role of dermatology providers in PsA care, highlighting the importance of screening patients with psoriasis for PsA in order to timely diagnose PsA and start treatment that can prevent or reduce joint damage. The second presentation addresses the wide range of PsA therapies and the latest evidence-based recommendations for treatment of PsA. The third presentation features a practical approach to patient-provider shared decision-making about treatment goals and treatment plan. This activity focuses on the recent advances and practical applications of available therapies, which have been shown to have efficacy for the treatment of psoriasis and PsA. It will not dive into the details on efficacy, safety, and risk data for every treatment option, because this is outside of the scope of this activity.

Intended Audience

The target audience is dermatologists. Other healthcare professionals, including rheumatologists, physician assistants, and nurse practitioners who treat patients with psoriatic arthritis, may benefit from participation in this educational activity.

Educational Objectives

Upon completion of the activity, participants should be able to:

  • Screen patients with psoriasis for PsA at each visit
  • Discuss Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) recommendations for treatment of PsA
  • Incorporate advances in treatment of PsA into care of patients with psoriasis and PsA to achieve desired treatment targets
  • Effectively engage patients with psoriasis and PsA in shared decision-making regarding treatment goals, development of treatment plan, and treatment modification

Fee Information

There is no fee for this educational activity.

Conflict Of Interest Disclosure Policy

Educational activities provided by Forefront Collaborative must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all relevant financial relationship(s) with commercial interest(s)*. For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias. Disclosures appear below.

*The ACCME defines a commercial interest as any entity producing, marketing, reselling, or distributing healthcare goods or services consumed by or used on patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests.

Faculty

Neil J. Korman, MD, PhD
Activity Chair
Director, Clinical Trials Unit
Clinical Director, Murdough Family Center for Psoriasis
Professor, Dermatology
University Hospitals Cleveland Medical Center
Case Western Reserve University School of Medicine
Cleveland, OH

Dr. Korman is an advisor for AbbVie Inc., Celgene Corporation, Eli Lilly and Company, Janssen Pharmaceuticals, Inc., and Regeneron Pharmaceuticals, Inc.; investigator for AbbVie Inc., Eli Lilly and Company, Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Pfizer Inc., and Regeneron Pharmaceuticals, Inc.; speaker for AbbVie Inc., Celgene Corporation, Eli Lilly and Company, Janssen Pharmaceuticals, Inc., and Novartis; and consultant for Novartis and Pfizer Inc.

April W. Armstrong, MD, MPH
Associate Dean for Clinical Research,
Associate Professor of Dermatology,
Director of Clinical Research, Clinical and Translational Science Institute
Director of Clinical Trials and Outcomes Research,
Director of Psoriasis Program,
Department of Dermatology
Keck School of Medicine of USC
Los Angeles, CA

Dr. Armstrong is a consultant for Novartis, Sanofi, Regeneron Pharmaceuticals, Inc., Pfizer Inc., Celgene Corporation, Modernizing Medicine, AbbVie Inc., Eli Lilly and Company, Merck & Co, Inc., and Janssen Pharmaceuticals, Inc.; speaker and researcher for Eli Lilly and Company, AbbVie Inc., and Janssen Pharmaceuticals, Inc.

Rebecca R. Muntean, MD, ND, FACR
Clinical Rheumatologist, Providence Health & Services
Faculty, University of Washington WWAMI Regional Medical Education
Faculty, Providence Spokane Internal Medicine
Investigator, Premier Clinical Research
Spokane and Providence Health & Services
Spokane, WA

Dr. Muntean is a speaker for Janssen Pharmaceuticals, Inc.

Accredited Provider Disclosure

The following individuals have indicated that neither they nor their spouses/partners have had, in the past 12 months, financial relationship(s) with commercial interests relative to the content of this CME activity:

Christine Tebben and Marianna Shershneva, MD, PhD, of Forefront Collaborative have no financial relationships to disclose relative to the content of this CME activity.

Credit

0.75

Type

AMA PRA Category 1 Credit(s)TM

Accreditation Statement

Forefront Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation Statement

Forefront Collaborative designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

This continuing medical education activity may include reference(s) to unlabeled or unapproved uses of drugs.

Disclaimer

The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views or recommendations of Forefront Collaborative.

Instructions

To obtain credit, a score of 80% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.

If you have any questions relating to the accreditation of this activity, please contact info@forefrontcollab.com.

SYSTEM REQUIREMENTS

Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
Add to Queue